II
RVNC

Inspire Investing’s Revance Therapeutics, Inc. RVNC Stock Holding History

Inspire Investing’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-131,892
Closed -$401K – 891
2024
Q4 		$401K Buy
131,892
+53,837
+69% +$235K 0.04% 546
2024
Q3 		$405K Sell
78,055
-61,024
-44% -$303K 0.04% 746
2024
Q2 		$357K Buy
139,079
+65,919
+90% +$225K 0.04% 374
2024
Q1 		$360K Buy
73,160
+29,645
+68% +$175K 0.04% 488
2023
Q4 		$382K Buy
43,515
+16,923
+64% +$139K 0.04% 683
2023
Q3 		$305K Buy
26,592
+14,151
+114% +$272K 0.04% 744
2023
Q2 		$315K Buy
12,441
+3,977
+47% +$124K 0.04% 502
2023
Q1 		$273K Sell
8,464
-4,334
-34% -$135K 0.03% 646
2022
Q4 		$236K Buy
12,798
+5,109
+66% +$117K 0.03% 452
2022
Q3 		$208K Sell
7,689
-7,851
-51% -$159K 0.03% 421
2022
Q2 		$215K Buy
15,540
+3,316
+27% +$51K 0.03% 361
2022
Q1 		$238K Sell
12,224
-3,183
-21% -$48.3K 0.03% 405
2021
Q4 		$251K Buy
+15,407
New +$257K 0.03% 421

Other funds holding RVNC

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Inspire Investing's RVNC Position: Q1 2025 in Review

Inspire Investing sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2025, closing a stake of 131,892 shares — an estimated $401K sold.

Inspire Investing first reported a position in RVNC in Q4 2021 and held it in 13 quarters. The position peaked at $405K in Q3 2024. 1 fund tracked by Wall St. Rank holds RVNC as of Q1 2025.

  • Inspire Investing reported no remaining Revance Therapeutics, Inc. position as of Q1 2025 after selling out during the quarter.
  • Inspire Investing sold 131,892 Revance Therapeutics, Inc. shares in Q1 2025, an estimated $401K.
  • Inspire Investing first reported a position in Revance Therapeutics, Inc. in Q4 2021 and held it in 13 quarters.
  • Inspire Investing's Revance Therapeutics, Inc. position peaked at $405K in Q3 2024.
  • 1 fund tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2025.

Based on Inspire Investing's 13F filing for Q1 2025, filed 3 Jun 2025.